Rosacea and gastrointestinal disorders: a population-based cohort study

British Journal of Dermatology

Volumn 176, Issue 1, 2017, Pages 100-106

  Egeberg, A ^a   Weinstock, L B ^b   Thyssen, E P ^b   Gislason, G H ^a,c,d   Thyssen, J P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Cardiovascular Epidemiology and Research   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL OVERGROWTH; CELIAC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HELICOBACTER INFECTION; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; ROSACEA; SMALL INTESTINE DISEASE; ULCERATIVE COLITIS; ADOLESCENT; AGED; CASE CONTROL STUDY; COMPLICATION; DENMARK; HELICOBACTER INFECTIONS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; SOCIOECONOMICS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; FEMALE; HELICOBACTER INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; ROSACEA; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 85010256380     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14930     Document Type: Article

References (40)

1. Lomholt G. Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 1964; 11:1–7.
2. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989; 69:419–23.
3. Tan J, Blume-Peytavi U, Ortonne JP et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol 2013; 169:555–62.
4. Schwab VD, Sulk M, Seeliger S et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol 2011; 15:53–62.
5. Al-Dabagh A, Davis SA, McMichael AJ, Feldman SR. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J 2014; 20:1–6.
6. Two AM, Wu W, Gallo RL et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol 2015; 72:749–58.
7. Watson WC, Paton E, Murray D. Small-bowel disease in rosacea. Lancet 1965; 1:47–50.
8. Li WQ, Cho E, Khalili H et al. Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women. Clin Gastroenterol Hepatol 2016; 14:220–5.
9. Walton S, Sheth M, Wyatt EH. Rosacea and ulcerative colitis: a possible association. J Clin Gastroenterol 1990; 12:513–5.
10. Romiti R, Jansen T, Heldwein W et al. Rosacea fulminans in a patient with Crohn's disease: a case report and review of the literature. Acta Derm Venereol 2000; 80:127–9.
11. Jansen T, Plewig G. Fulminating rosacea conglobata (rosacea fulminans) and ulcerative colitis. Br J Dermatol 1997; 137:830–1.
12. Gravina A, Federico A, Ruocco E et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterol J 2015; 3:17–24.
13. Parodi A, Paolino S, Greco A et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6:759–64.
14. Abram K, Silm H, Maaroos HI et al. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010; 24:565–71.
15. Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol 2013; 68:875–6.
16. Gasbarrini A, Franceschi F. Does H. pylori infection play a role in idiopathic thrombocytopenic purpura and in other autoimmune diseases? Am J Gastroenterol 2005; 100:1271–3.
17. Chang AL, Raber I, Xu J et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol 2015; 135:1548–55.
18. Rainer BM, Fischer AH, Luz Felipe da Silva D et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case–control study. J Am Acad Dermatol 2015; 73:604–8.
19. von Elm E, Altman DG, Egger M et al. The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18:800–4.
20. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29:541–9.
21. Andersen TF, Madsen M, Jorgensen J et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46:263–8.
22. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44:445–8.
23. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health 2011; 39:103–5.
24. Bytzer P, Dahlerup JF, Eriksen JR et al. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull 2011; 58:C4271.
25. Egeberg A, Mallbris L, Gislason GH et al. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 2016; 136:93–8.
26. Egeberg A, Gislason G, Hansen P. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 2016; 152:1–6.
27. Spoendlin J, Karatas G, Furlano RI et al. Rosacea in patients with ulcerative colitis and Crohn's disease: a population-based case–control study. Inflamm Bowel Dis 2016; 22:680–7.
28. Goyette P, Boucher G, Mallon D et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015; 47:172–9.
29. Bamford JT, Tilden RL, Blankush JL et al. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol 1999; 135:659–63.
30. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51:327–41.
31. Gedik GK, Karaduman A, Sivri B et al. Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms? J Eur Acad Dermatol Venereol 2005; 19:398–9.
32. Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol 2013; 69:1025–32.
33. Szlachcic A. The link between Helicobacter pylori infection and rosacea. J Eur Acad Dermatol Venereol 2002; 16:328–33.
34. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69:S27–35.
35. Utas S, Ozbakir O, Turasan A et al. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol 1999; 40:433–5.
36. Prantera C, Berto E, Scribano ML et al. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30:602–6.
37. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73(Suppl. 1):13–27.
38. Fonager K, Sorensen HT, Rasmussen SN et al. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 1996; 31:154–9.
39. Litt JZ. Steroid-induced rosacea. Am Fam Physician 1993; 48:67–71.
40. Margolis DJ, Fanelli M, Hoffstad O et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010; 105:2610–6.